World Rural Health Conference
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 2267
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents 
REVIEW ARTICLE
Year : 2016  |  Volume : 5  |  Issue : 3  |  Page : 533-538  

Urinary tract cancers: An overview for general practice


Department of Medicine, Redcliffe Hospital, Queensland, Australia

Date of Web Publication30-Dec-2016

Correspondence Address:
Julian P Yaxley
Department of Medicine, Redcliffe Hospital, Queensland
Australia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2249-4863.197258

Rights and Permissions
  Abstract 

Urinary tract cancers are common and comprise a gamut of lesions ranging from small benign tumors to aggressive neoplasms with high mortality. The predominant urinary tract malignancy is bladder cancer. The clinical challenge is early detection and adequate follow-up because recurrence is high and delayed diagnosis is associated with poor prognosis. Primary care physicians form a key part of the management apparatus for these patients and may be responsible for ensuring adequate ongoing surveillance. This article aims to outline the evaluation of patients in whom urinary tract cancer is suspected and briefly review the general principles of treatment.

Keywords: Cancer, hematuria, screening, transitional cell, urothelial


How to cite this article:
Yaxley JP. Urinary tract cancers: An overview for general practice. J Family Med Prim Care 2016;5:533-8

How to cite this URL:
Yaxley JP. Urinary tract cancers: An overview for general practice. J Family Med Prim Care [serial online] 2016 [cited 2019 Oct 20];5:533-8. Available from: http://www.jfmpc.com/text.asp?2016/5/3/533/197258


  Introduction Top


The urinary tract is lined by epithelium extending from the renal collecting tubules proximally to the urethral meatus distally. These epithelial cells are known as the urothelium or transitional cells. They are highly specialized cells with elasticity and variable shape. Any segment of the urothelium can be affected by malignant transformation. Greater than 90% of urinary tract cancers are transitional cell carcinomas (TCC) known today as urothelial carcinomas (UC). [1] Rarer cancers include squamous cell carcinoma, small cell carcinoma, and adenocarcinoma. Benign neoplasms are also sometimes seen.

This article is intended to provide an overview of the biology and clinical features of urinary tract cancer and to offer a basic approach to diagnosis and treatment. While the varieties of malignancy are manifold [Table 1] most are very uncommon, and content of this review is limited to UC.
Table 1: Histological subtypes of urinary tract cancers


Click here to view



  Bladder Cancer Top


Etiology and epidemiology

Bladder cancer is one of the most common cancers, and its incidence continues to rise. It accounts for 3% of new cancers and is the second most common urological cancer. [2],[3],[4] The precise mechanisms of etiopathogenesis are unestablished, but there is most likely an interplay between environmental and genetic factors. In contrast with most tumors, the risk of bladder cancer is unrelated to family history. [5],[6] The mean age of diagnosis is 65 years of age with the disease more frequent in men than women. [2],[7]

There are several well-known risk factors for the development of bladder cancer. Cigarette smoking is the strongest risk factor and is implicated in 60% of cases. [7] Certain occupational exposures are also associated with bladder cancer, typically of workers in chemical and textile industries. [8] Prior radiation exposure also increases risk.

Clinical manifestations

Painless macroscopic hematuria is the presenting symptom in 85%-90% of patients. [7],[9] It is a frequent reason for consulting a primary care physician. In a small number of cases that complaint is accompanied by urinary storage symptoms, particularly with high-grade tumors. Dysuria is the second most common initial complaint quoted to family physicians, which leads to a diagnosis of bladder cancer. [10] Symptoms are often intermittent which can lead to delays in diagnosis. Features occasionally seen in advanced disease include bone pain from metastasis, retroperitoneal muscle-invasive tumors causing flank pain, and ureteric obstruction due to bladder or regional invasion.

A complete physical examination is mandatory and should be performed in all patients with suspected bladder cancer. There are usually no physical signs in early disease. In more advanced disease, cachexia, lymphadenopathy, and bony tenderness are common findings. Very rarely, large volume tumors may produce a palpable abdominal or rectal mass.

Investigations

Macroscopic hematuria is a red flag for malignancy and always requires full urologic workup. It should be considered malignant until proven otherwise. The likelihood of UC in patients with frank hematuria is approximately 12%. [11],[12] The entire urinary tract requires evaluation in this instance to establish the cause of bleeding. A suggested complete workup includes blood and urine tests, imaging studies, and cystoscopy [Table 2].
Table 2: Suggested investigations for macroscopic haematuria


Click here to view


After exclusion of a malignant cause for bleeding, other nephrologic and genitourinary lesions can be considered [Figure 1].
Figure 1: Differential diagnosis of macroscopic hematuria


Click here to view


Microscopic hematuria

The best approach to microscopic hematuria is uncertain. Urinalysis is a basic and widely used tool [Table 3]. Urine dipstick is very sensitive for bleeding but is extremely nonspecific, and the rate of false positives is high. Confirmation and quantification are therefore required with microscopy. Microscopic hematuria is defined as at least three red cells per high powered field visible under microscopy. [13] Most laboratories report in the International System of Units with hematuria classified as a urinary erythrocyte count ≥10 × 10 6 /L.
Table 3: Investigations useful in the diagnosis of urinary tracts cancers


Click here to view


Incidental detection of microhematuria is a common phenomenon. In early stages, most patients with bladder cancer have microscopic hematuria. However, the prevalence of microhematuria in healthy individuals is approximately 10%-15% and the decision about which patients to investigate may thus be difficult. [15],[19] The first step is a repeat urine sample at least several days after the initial positive specimen because many incidental cases are transient. Asymptomatic patients with a single incidental microhematuria sample seldom warrant further workup for cancer. [15]

The diagnostic approach should be individualized. Only a small number of cases, at approximately 2%, of persistent microscopic hematuria are attributable to malignancy. [11] If a benign cause is likely, then further investigations for malignancy can probably be safely omitted [Figure 2]. If renal function is impaired or the urinalysis suggests intrinsic renal disease, such as red cell casts or urine eosinophils, then referral to a nephrologist is appropriate. If not thought to be cancer, evaluation and management are guided by the provisional diagnosis.
Figure 2: Differential diagnosis of microscopic hematuria


Click here to view


Patients with features suggestive for cancer or in whom an alternative diagnosis is not obvious should be further evaluated to exclude urinary tract malignancy. The American Urological Association (AUA) has developed guidelines for investigating microscopic hematuria. [15] Patients are stratified by risk with a baseline screen consisting of urine cytology and computed tomography (CT) urography in individuals with lower risk. High-risk features listed by the AUA include age >40, a history of smoking, industrial chemical exposures, or lower urinary tract symptoms. Many authors propose that age alone should not be characterized as a high-risk factor and that discretion is exercised when no other high-risk factors are evident. Universal full urologic evaluation in patients older than forty without other high-risk features would likely lead to over-investigation and expose patients to unnecessary risk and cost. [12],[20] Limiting testing to urine cytology and CT urography may be adequate in patients at low risk although some urologists elect to perform cystoscopy [Figure 3].
Figure 3: A suggested algorithm for the diagnostic approach to microscopic hematuria. Generally consistent with American Urological Association guidelines however some authorities do not consider age alone to be a high-risk factor

Click here to view


Patients with a negative cancer workup do require follow-up. Other urological or renal pathologies should be considered and managed as deemed appropriate. Re-evaluation for cancer is necessary in patients who develop interval changes such as urinary symptoms or macroscopic hematuria. Persisting microscopic hematuria does not in itself require repeated evaluation for cancer in any age but should prompt nephrology referral to exclude medical kidney disease. [8]

Management

Treatment decisions for bladder TCC depend on tumor grade and stage. These strongly correlate with tumor recurrence, progression, and survival. Most tumors are not muscle invasive at the time of diagnosis. There is a relatively large list of options for treatment, full discussion of which is beyond the scope of this article. Specialist treatment may involve chemotherapy, radiotherapy, surgery, or a combination of these. Chemotherapy is commonly administered intravesically through a urinary catheter but may also be systemic. Radical cystectomy is associated with substantial morbidity and has led to various bladder-sparing surgical techniques.

Most pertinent to the primary care setting is the need for adequate follow-up. Tumor recurrence typically occurs within 12 months of definitive treatment and patients are usually closely followed by the treating urologist for the first few years after treatment. Long-term surveillance is an important responsibility of the general practitioner, which is usually conducted in cooperation with the treating specialist. More than 50% of high-grade tumors recur, and most patients require lifelong annual testing. [1],[21],[22],[23] Early identification of tumor recurrence benefits the patient. The protocol for follow-up usually involves a combination of regular urine cytology, repeat CT, and regular check cystoscopies.

It is important that physicians in primary care have a working knowledge of the management principles for bladder cancer. Patients frequently present to their general practitioner with questions about the disease and its proposed treatment or with complications of treatment.


  Ureteric and Renal Pelvic Cancer Top


Etiology and epidemiology

Upper urinary tract urothelium shares many morphologic properties with bladder mucosa. The vast majority of upper tract cancers are UCs. The pathogenesis of these neoplasms is similar to bladder cancer. Ureteric cancer and cancer of the renal pelvis are far less common than bladder cancer, comprising only 4% of urothelial malignancies. [9]

Upper tract UC is frequently multifocal. Tumors often present with concurrent bladder cancer or with bilateral lesions. In one series, 44% of patients with upper tract cancer developed a bladder tumor over a mean interval of 13.9 months. [24] Approximately 5% of patients develop upper tract tumors of the contralateral side. [25] There are two theories explaining these observations. One hypothesis, the "field cancerization effect," is that the entire urothelium is bathed in the same carcinogenic material, giving rise to the development of distant lesions. The other is the "monoclonality" hypothesis of intraluminal seeding and intraepithelial cell migration.

While many patients with upper tract cancers develop bladder tumors, patients with bladder cancer seldom develop an upper tract lesion. This is probably because of longer exposure to urinary carcinogens in the bladder during bladder filling.

Clinical manifestations

Macroscopic hematuria is noted in 90% of patients. [9] This is classically painless and may be accompanied by lower urinary tract symptoms. Flank pain is a relatively common problem due to ureteral obstruction from blood clots.

Investigations

The approach to diagnosis of ureteric or renal pelvic UC is analogous to that for bladder cancer. Frank hematuria necessitates a full urologic workup while patients with microscopic hematuria should be risk stratified. Urine cytology is less reliable for detecting upper tract cancers, and a pathologist with particular expertise in this area is mandatory to interpret such specimens. Low-grade upper tract TCC is not usually associated with positive urine cytology.

Management

Surgery is the only potentially curative measure for upper urinary tract cancer. Nephroureterectomy is the procedure of choice, which is usually performed in addition to excision of a cuff of bladder. There is a move toward more conservative ablative operations in select patients, which may be indicated in patients with a solitary kidney, bilateral malignancy, or those patients with localized low-grade disease. Adjuvant chemotherapy and radiation therapy have been trialed for upper tract cancers, but their efficacy is unknown.

Ongoing follow-up in the primary care environment is of vital importance. Like bladder cancer, the natural history of renal pelvic and ureteric cancers is punctuated by tumor recurrence. Lifelong surveillance is necessary and is often conducted in unison between specialist and general practitioner.


  Screening Top


Urinary biomarkers

Several new methods for detecting urine biomarkers are emerging. They identify various proteins in urine exposed to neoplasia and overcome shortcomings of the modalities currently available. Assays under development include bladder tumor antigen, nuclear matrix protein 22, and fibrin degradation product. These are available in some areas of the world but have not been widely adopted because of their limited utility. Experimental results are promising, but most kits still achieve sensitivities of <90%. [9],[26],[27],[28] In addition, specificity has proven low, and the cost is prohibitively expensive. Clinical trials are ongoing, and the optimal role of urinary biomarkers as a screening tool or in the management of bladder cancer is yet to be determined.

Recommendations

Screening refers to the detection of disease in patients without symptoms. An ideal screening test is inexpensive, sensitive, and specific. Bladder cancer is a potential candidate for screening because of its prevalence and significance. However, no major organizations recommend bladder cancer screening in asymptomatic adults. [29],[30],[31] There is no evidence that population screening improves patient outcomes or alters the natural history of the disease. [32],[33],[34] Furthermore, identification of high-risk groups that may benefit from screening has been unsuccessful. Screening is limited by feasibility, cost-effectiveness, and the potential harms of invasive tests. The role of screening for bladder cancer will continue to be revaluated as advancements in testing modalities are refined.


  Summary Top


Urinary tract cancers are common and impose a significant cost burden on society. Frank hematuria warrants a full urological workup in all patients and should be considered malignant until proven otherwise, particularly in individuals older than 40 years of age. The approach to microscopic hematuria is controversial. Patients with risk factors for malignancy or in whom a cause is not clear should undergo further testing. The natural history of UC is typified by tumor recurrence, and the primary care setting is a pivotal space to encourage patient adherence to surveillance protocols following cancer treatment. Despite its prevalence, screening for bladder cancer is not supported by evidence and cannot be recommended.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Bladder Cancer Clinical Guideline Update Panel. Guideline for the Management of Non-muscle Invasive Bladder Cancer: 2007 update. Linthicum: American Urological Association; 2007.  Back to cited text no. 1
    
2.
Australian Institute of Health and Welfare. Cancer Survival and Prevalence in Australia: Period Estimates from 1982 to 2010. Canberra: Australian Institute of Health and Welfare; 2012.  Back to cited text no. 2
    
3.
Tjandra J, Clunie G, Kaye A, Smith J. Textbook of Surgery. 3 rd ed. Carlton: Blackwell Publishing Asia Pvt. Ltd.; 2006.  Back to cited text no. 3
    
4.
Austrlian Institute of Health and Welfare. Cancer in Australia: An Overview 2012. Canberra: Australian Institute of Health and Welfare; 2012.  Back to cited text no. 4
    
5.
Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008;26:451-64.  Back to cited text no. 5
    
6.
Wein A, Kavoussi L, Novick A, Partin A, Peters C. Campbell Walsh Urology. 9 th ed. Philadelphia: Saunders Elsevier Inc.; 2007.  Back to cited text no. 6
    
7.
Woodford C, Yao C. Essential Med Notes 2013. Toronto: Toronto Notes for Medical Students Inc.; 2013.  Back to cited text no. 7
    
8.
Althunayan A, Kassouf W. Asymptomatic microscopic haematuria: Clinical significance and evaluation. Urology 2011;17:1-7.  Back to cited text no. 8
    
9.
McAninch J, Lue T. Smith and Tanagho′s General Urology. 18 th ed. New York: McGraw Hill Companies Inc.; 2013.  Back to cited text no. 9
    
10.
Shephard EA, Stapley S, Neal RD, Rose P, Walter FM, Hamilton WT. Clinical features of bladder cancer in primary care. Br J Gen Pract 2012;62:e598-604.  Back to cited text no. 10
    
11.
Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013;88:129-38.  Back to cited text no. 11
    
12.
Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524-7.  Back to cited text no. 12
    
13.
Howard RS, Golin AL. Long-term follow-up of asymptomatic microhematuria. J Urol 1991;145:335-6.  Back to cited text no. 13
    
14.
Thaller TR, Wang LP. Evaluation of asymptomatic microscopic hematuria in adults. Am Fam Physician 1999;60:1143-52, 1154.  Back to cited text no. 14
    
15.
Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012;188 6 Suppl: 2473-81.  Back to cited text no. 15
    
16.
Lisanti CJ, Toffoli TJ, Stringer MT, DeWitt RM, Schwope RB. CT evaluation of the upper urinary tract in adults younger than 50 years with asymptomatic microscopic hematuria: Is IV contrast enhancement needed? AJR Am J Roentgenol 2014;203:615-9.  Back to cited text no. 16
    
17.
Sudakoff GS, Dunn DP, Guralnick ML, Hellman RS, Eastwood D, See WA. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008;179:862-7.  Back to cited text no. 17
    
18.
Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: Results for 778 patients from a hospital haematuria clinic. BJU Int 2012;110:84-94.  Back to cited text no. 18
    
19.
Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. Br Med J (Clin Res Ed) 1984;288:20-2.  Back to cited text no. 19
    
20.
Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med 2003;348:2330-8.  Back to cited text no. 20
    
21.
Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.  Back to cited text no. 21
    
22.
Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.  Back to cited text no. 22
    
23.
Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67 3 Suppl 1:48-54.  Back to cited text no. 23
    
24.
Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49.  Back to cited text no. 24
    
25.
Raman JD, Sosa RE, Vaughan ED Jr., Scherr DS. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007;69:251-4.  Back to cited text no. 25
    
26.
Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620-6.  Back to cited text no. 26
    
27.
Mitra AP, Cote RJ. Molecular screening for bladder cancer: Progress and potential. Nat Rev Urol 2010;7:11-20.  Back to cited text no. 27
    
28.
Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60:484-92.  Back to cited text no. 28
    
29.
National Cancer Institute. Bladder and Other Urothelial Cancers Screening; 2015. Available from: http://www.cancer.gov/types/bladder/patient/bladder-screening-pdq. [Last accessed on 2016 Feb 12].  Back to cited text no. 29
    
30.
Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol 2013;63:4-15.  Back to cited text no. 30
    
31.
American Cancer Society. American Cancer Society Guidelines for the Early Detection of Cancer; 2015. Available from: http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer. [Last accessed on 2016 Feb 12].  Back to cited text no. 31
    
32.
Messing E, Madeb R, Young T, Gilchrist K, Bram L, Greenberg E, et al. Long-term outcome of haematuria home screening for bladder cancer in men. Cancer 2006;107:2173-9.  Back to cited text no. 32
    
33.
Bangma C, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, et al. Outcomes of a bladder cancer screening program using home haematuria testing and molecular markers. Eur Urol 2013;64:41-7.  Back to cited text no. 33
    
34.
Chou R, Dana T. Screening adults for bladder cancer: A review of the evidence for the U.S. preventive services task force. Ann Intern Med 2010;153:461-8.  Back to cited text no. 34
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]


This article has been cited by
1 Cancers of Urinary System; Prevalence, Demographic
Zahra Tolou Ghamari
Jundishapur Journal of Chronic Disease Care. 2019; In Press(In Press)
[Pubmed] | [DOI]
2 Synergistic effect of phototherapy and chemotherapy on bladder cancer cells
Mehdi Shakibaie,Maryam Vaezjalali,Hashem Rafii-Tabar,Pezhman Sasanpour
Journal of Photochemistry and Photobiology B: Biology. 2019; 193: 148
[Pubmed] | [DOI]
3 Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder
Jen-Tai Lin,Ti-Chun Chan,Chien-Feng Li,Steven K.H. Huan,Yu-Feng Tian,Peir-In Liang,Cheng-Tang Pan,Yow-Ling Shiue
APMIS. 2019; 127(4): 170
[Pubmed] | [DOI]
4 Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications
Melisa B. Nicoud,Karina Formoso,Vanina A. Medina
Frontiers in Pharmacology. 2019; 10
[Pubmed] | [DOI]
5 Partial resection of the urinary bladder in swine and sheep and replacement of the resected segment by biologically inert patches
Željko Vidas,Franjo Jurenec,Tugomir Karadjole,Marko Samardžija,Goran Bacic,Ana Beck,Nino Macešic
Acta Veterinaria Brno. 2018; 87(4): 347
[Pubmed] | [DOI]
6 Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer
Sheng Li,Xiaoping Liu,Tongzu Liu,Xiangyu Meng,Xiaohong Yin,Cheng Fang,Di Huang,Yue Cao,Hong Weng,Xiantao Zeng,Xinghuan Wang
Frontiers in Physiology. 2017; 8
[Pubmed] | [DOI]
7 Metastatic Disease or an Early Stage Bladder Cancer? A Difficult Question
Ozge Keskin
Journal of Cancer Prevention & Current Research. 2017; 8(1)
[Pubmed] | [DOI]



 

Top
   
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   Abstract
  Introduction
  Bladder Cancer
   Ureteric and Ren...
  Screening
  Summary
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed1304    
    Printed12    
    Emailed0    
    PDF Downloaded214    
    Comments [Add]    
    Cited by others 7    

Recommend this journal